Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy

Pulmonary Pharmacology and Therapeutics

Volumn 31, Issue , 2015, Pages 123-129

  Novelli, Federica ^a   Latorre, M ^ad   Vergura, Letizia ^a   Caiaffa, M F ^o   Camiciottoli, Gianna ^c   Guarnieri, G ^v   Matucci, Andrea ^e   Macchia, Luigi ^f   Vianello, Andrea ^g   Vultaggio, Alessandra ^e   Celi, Alessandro ^a   Cazzola, Mario ^h,t   Paggiaro, Pierluigi ^a   Camiciottoli, G ⁱ   Maselli, R ^j   Pelaia, G ^j   Busceti, M T ^j   Sabato, E ^k   Cagnazzo, M G ^k   Colombo, F ^l   Palumbo, L ^l   Ravazzi, A ^m   Bucca, C ⁿ   Berra, A ^p   Calabrese, C ^q   Stanziola, A A ^q   Schino, P ^r   Di Gioacchino, M ^s   Segreti, A ^t   Pastorello, E A ^u   Scibilia, G ^u   Vianello, A ^v   Marchi, M R ^v   Paladini, L ^v   Baglioni, S ^w   Abbritti, M ^w   Almerigogna, F ^e   Matucci, A ^e   Vultaggio, A ^e   Maggi, E ^e   Maestrelli, P ^v   Steinhilber, G ^x   Bonavia, M ^y   5Rottoli, P ^z   Bargagli, E ^z   Senna, G ^aa   Caminati, M ^aa   Macchia, L ^ab   Bellia, V ^ac   Scichilone, N ^ac   Paggiaro, P ^ad   Novelli, F ^ad   Vergura, L ^ad   more..

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF FOGGIA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

^f UNIVERSITY OF BARI   (Italy)

^g UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^h UNIVERSITY OF ROME TOR VERGATA   (Italy)

ⁱ Careggi   (Italy)

^j Policlinico Mater Domini   (Italy)

^k Ospedale Melli e San Pietro Vernotico e Brindisi   (Italy)

^l OSPEDALE DI CIRCOLO   (Italy)

^m Ospedale Provinciale sant'Anna   (Italy)

ⁿ Rianimazione ed Emergenze AOU Città della Salute e della Scienza   (Italy)

^o AOU Ospedali Riuniti   (Italy)

^p Unit Complessa di Pneumologia   (Italy)

^q MONALDI HOSPITAL   (Italy)

^r MIULLI GENERAL HOSPITAL   (Italy)

^s Ospedale Clinicizzato SS Annunziata   (Italy)

^t TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^u OSPEDALE NIGUARDA CA GRANDA   (Italy)

^v INFN Padova   (Italy)

^w UO Pneumologia e Unita di Terapia Intensiva AO di Perugia   (Italy)

^x Spedali Civili   (Italy)

^y Ospedale La Colletta   (Italy)

^z AOU Siena   (Italy)

^aa UNIVERSITY HOSPITAL OF VERONA   (Italy)

^ab POLICLINICO   (Italy)

^ac AO Ospedali Riuniti Villa Sofia Cervello   (Italy)

^ad UNIVERSITY HOSPITAL OF PISA   (Italy)

more..

Author keywords

Asthma; Comorbidities; Control; Exacerbations; Exhaled nitric oxide; Omalizumab

Indexed keywords

CORTICOSTEROID; LEUKOTRIENE DERIVATIVE; OMALIZUMAB; THEOPHYLLINE; TIOTROPIUM BROMIDE; ANTIASTHMATIC AGENT; AUTACOID;

ADULT; ARTICLE; ASTHMA; CHRONIC RHINOSINUSITIS; COMORBIDITY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE CONTROL; DRUG HYPERSENSITIVITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; ITALY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NOSE POLYP; OBESITY; OBSERVATIONAL STUDY; PREVALENCE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; LUNG FUNCTION TEST; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; ANTI-ASTHMATIC AGENTS; ASTHMA; COMORBIDITY; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; ITALY; MALE; MIDDLE AGED; OMALIZUMAB; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX;

EID: 84926317720     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2014.09.007     Document Type: Article

References (28)

1. Antonicelli L., Bucca C., Neri M., De Benedetto F., Sabbatani P., Bonifazi F., et al. Asthma severity and medical resource utilisation. Eur Respir J 2004, 23:723-729.
2. Chipps B.E., Zeiger R.S., Borish L., Wenzel S.E., Yegin A., Hayden M.L., et al. Key findings and clinical implications from the epidemiology and natural history of asthma: outcomes and treatment Regimens (TENOR) study. JAllergy Clin Immunol 2012, 130:332-342. TENOR Study Group.
3. Holgate S.T., Djukanović R., Casale T., Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy 2005, 35:408-416.
4. Sullivan S.D., Turk F. An evaluation of the cost-effectiveness of omalizumab for the treatment of severe allergic asthma. Allergy 2008, 63:670-684.
5. Humbert M., Beasley R., Ayres J., Slavin R., Hébert J., Bousquet J., et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): innovate. Allergy 2005, 60:309-316.
6. Niven R., Chung K.F., Panahloo Z., Blogg M., Ayre G. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study. Respir Med 2008, 102:1371-1378.
7. Hanania N.A., Alpan O., Hamilos D.L., Condemi J.J., Reves-Rivera I., Zhu J., et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Int Med 2011, 154:573-582.
8. Molimard M., de Blay F., Didier A., Le Gros V. Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med 2008, 102:71-76.
9. Korn S., Thielen A., Seyfried S., Taube C., Kornmann O., Buhl R. Omalizumab in patients with severe persistent allergic asthma in a real-life setting in Germany. Respir Med 2009, 103:1725-1731.
10. Brusselle G., Michils A., Louis R., Dupont L., Van de Maele B., Delobbe A., et al. Real-life effectiveness of omalizumab in patients with severe persistent allergic asthma: the PERSIST study. Respir Med 2009, 103:1633-1642.
11. Storms W., Bowdish M.S., Farrar J.R. Omalizumab and asthma control in patients with moderate-to-severe allergic asthma: a 6-year pragmatic data review. Allergy Asthma Proc 2010, 33:172-177.
12. Tzortzaki E.G., Georgiou A., Kampas D., Lemessios M., Markatos M., Adamidi T., et al. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern mediterranean real-life experience. Pulm Pharmacol Ther 2012, 25:77-82.
13. Lafeuille M.H., Dean J., Zhang J., Duh M.S., Gorsh B., Lefebvre P. Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma. Ann Allergy Asthma Immunol 2012, 109:59-64.
14. Braunstahl G.J., Chen C.W., Maykut R., Georgiou P., Peachey G., Bruce J. The eXpeRience registry: the real-world effectiveness of omalizumab in allergic asthma. Respir Med 2013, 107:1141-1151.
15. Chen H., Eisner M.D., Haselkorn T., Trzaskoma B. Concomitant asthma medications in moderate-to-severe allergic asthma treated with omalizumab. Respir Med 2013, 107:60-67.
16. Grimaldi-Bensouda L., Zureik M., Aubier M., Humbert M., Levy J., Benichou J., et al. Does omalizumab make a difference to the real-life treatment of asthma exacerbations?: results from a large cohort of patients with severe uncontrolled asthma. Chest 2013, 143:398-405. Pharmacoepidemiology of Asthma and Xolair (PAX) Study Group.
17. Barnes N., Menzies -Gow A., Mansyr A.H., Spencer D., Percival F., Radwan A., et al. Effectiveness of omalizumab in severe allergic asthma: a retrospective UK real world study. JAsthma 2013, 50:529-536.
18. Deschildre A., Marguet C., Salleron J., Pin I., Rittié J.L., Derelle J., et al. Add-on omalizumab in children with severe allergic asthma: a one year rel life survey. Eur Respir J 2013, 42:1224-1233.
19. Cazzola M., Camiciottoli G., Bonavia M., Gulotta C., Ravazzi A., Alessandrini A., et al. Italian real-life experience of omalizumab. Respir Med 2010, 104:1410-1416.
20. Quanjer P.H., Tammeling G.J., Cotes J.E., Fabbri L.M., Matthys H., Pedersen O.F., et al. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European community for steel and coal. Official statement of the European respiratory society. Eur Respir J 1993, 6(Suppl.16):5-40.
21. American Thoracic Society, European Respiratory Society ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005, 171:912-930.
22. Luskin A.T., Chipps B.E., Rasouliyan L., Miller D.P., Haselkorn T., Dorenbaum A. Impact of asthma exacerbations and asthma triggers on asthma-related quality of life in patients with severe or difficult-to-treat asthma. JAllergy Clin Immunol Pract 2014, 2:544-552.
23. Zhu R., Zheng Y., Putnam W.S., Visich J., Eisner M.D., Matthews J.G., et al. Population-based efficacy modeling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapy. AAPS J 2013, 15:559-570.
24. Haldar P., Pavord I.D., Shaw D.E., Berry M.A., Thomas M., Brightling C.E., et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008, 178:218-224.
25. Melosini L., Dente F.L., Bacci E., Bartoli M.L., Cianchetti S., Costa F., et al. Asthma control test (ACT): comparison with clinical, functional, and biological markers of asthma control. JAsthma 2012, 49:317-323.
26. van Veen I.H., Ten Brinke A., Sterk P.J., Sont J.K., Gauw S.A., Rabe K.F., et al. Exhaled nitric oxide predicts lung function decline in difficult-to-treat asthma. Eur Respir J 2008, 32:344-349.
27. ten Brinke A., Sterk P.J., Masclee A.A., Spinhoven P., Schmidt J.T., Zwinderman A.H., et al. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J 2005 Nov, 26(5):812-818.
28. Zureik M., Neukirch C., Leynaert B., Liard R., Bousquet J., Neukirch F. European community respiratory health survey. Sensitisation to airborne moulds and severity of asthma: cross sectional study from European community respiratory health survey. BMJ 2002, 325:411-414.